Literature DB >> 31466582

Systemic Therapies for Advanced Melanoma.

Leonora Bomar1, Aditi Senithilnathan2, Christine Ahn2.   

Abstract

The incidence of metastatic melanoma continues to increase each decade. Although surgical treatment is often curative for localized stage I and stage II disease, the median survival for patients with distant metastases is less than 1 year. The last 2 decades have witnessed a breakthrough in therapeutic options with the development of immune checkpoint inhibitors, small molecule targeted therapy, and oncolytic viral therapy. This article provides an overview of the treatment options available for advanced melanoma, including chemotherapy, targeted therapy, immunotherapy, interleukin-2, and oncolytic viral agents.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Advanced; Anti-PD1 agents; BRAF inhibitors; Chemotherapy; Ipilimumab; MEK inhibitors; Melanoma; Metastatic

Mesh:

Substances:

Year:  2019        PMID: 31466582     DOI: 10.1016/j.det.2019.05.001

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  12 in total

Review 1.  Donor-Transmitted Melanoma: Is It Still Bothering Us?

Authors:  Leila Abdullayeva
Journal:  Curr Treat Options Oncol       Date:  2020-04-23

2.  A novel endoplasmic reticulum stress-related lncRNA prognostic risk model for cutaneous melanoma.

Authors:  An-An Li; Fan Li; Min Lan; Yu Zhang; Dong Xie; Mei-Ying Yan
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-10       Impact factor: 4.322

3.  Immunotherapy-Induced Auto-Splenectomy in a Patient of Malignant Melanoma.

Authors:  Syed Ehsanullah; Azharuddin Muhammad; Syed Hasan; John M Richart
Journal:  Cureus       Date:  2022-05-17

Review 4.  Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions.

Authors:  Massimo Ralli; Andrea Botticelli; Irene Claudia Visconti; Diletta Angeletti; Marco Fiore; Paolo Marchetti; Alessandro Lambiase; Marco de Vincentiis; Antonio Greco
Journal:  J Immunol Res       Date:  2020-06-28       Impact factor: 4.818

5.  Evolving management of positive regional lymph nodes in melanoma: Past, present and future directions.

Authors:  Rachel A Fayne; Francisco I Macedo; Steven E Rodgers; Mecker G Möller
Journal:  Oncol Rev       Date:  2019-11-28

6.  Triphenylphosphonium derivatives disrupt metabolism and inhibit melanoma growth in vivo when delivered via a thermosensitive hydrogel.

Authors:  Kyle C Kloepping; Alora S Kraus; Devin K Hedlund; Colette M Gnade; Brett A Wagner; Michael L McCormick; Melissa A Fath; Dongrim Seol; Tae-Hong Lim; Garry R Buettner; Prabhat C Goswami; F Christopher Pigge; Douglas R Spitz; Michael K Schultz
Journal:  PLoS One       Date:  2020-12-30       Impact factor: 3.240

7.  Combination immunotherapy of chlorogenic acid liposomes modified with sialic acid and PD-1 blockers effectively enhances the anti-tumor immune response and therapeutic effects.

Authors:  Xixi Li; Shunyao Zhu; Ping Yin; Shuangshuang Zhang; Juewen Xu; Qin Zhang; Senlin Shi; Ting Zhang
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

Review 8.  Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma.

Authors:  Otto Luiz Dutra Cerqueira; Fernanda Antunes; Nadine G Assis; Elaine C Cardoso; Maria A Clavijo-Salomón; Ana C Domingues; Nayara G Tessarollo; Bryan E Strauss
Journal:  Front Mol Biosci       Date:  2022-04-14

Review 9.  Targeting Genome Stability in Melanoma-A New Approach to an Old Field.

Authors:  Marta Osrodek; Michal Wozniak
Journal:  Int J Mol Sci       Date:  2021-03-28       Impact factor: 5.923

10.  Improved detection of in-transit metastases of malignant melanoma with BSREM reconstruction in digital [18F]FDG PET/CT.

Authors:  Virginia Liberini; Michael Messerli; Lars Husmann; Ken Kudura; Hannes Grünig; Alexander Maurer; Stephan Skawran; Erika Orita; Daniele A Pizzuto; Désirée Deandreis; Reinhard Dummer; Joanna Mangana; Daniela Mihic-Probst; Niels Rupp; Martin W Huellner
Journal:  Eur Radiol       Date:  2021-03-25       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.